Postmenopausal state
Item
postmenopausal females
boolean
C0232970 (UMLS CUI [1])
Breast Carcinoma
Item
histologically or cytologically confirmed diagnosis of breast carcinoma
boolean
C0678222 (UMLS CUI [1])
Locally advanced breast cancer | Breast cancer recurrent Locally Inoperable | Carcinoma breast stage IV | Disease Progression
Item
locally advanced or locally recurrent inoperable or metastatic breast carcinoma with documented disease progression
boolean
C3495949 (UMLS CUI [1])
C0278493 (UMLS CUI [2,1])
C1517927 (UMLS CUI [2,2])
C0205187 (UMLS CUI [2,3])
C0278488 (UMLS CUI [3])
C0242656 (UMLS CUI [4])
Estrogen Receptor and/or Progesterone Receptor Positive | Response to Cancer hormonal therapy First line | Response to Cancer hormonal therapy Second line
Item
has laboratory documentation of positive estrogen receptor (er) and/or progesterone receptor (pgr) status, and has responded to the standard first or second line hormonal anti-tumor therapy given
boolean
C3640067 (UMLS CUI [1])
C0521982 (UMLS CUI [2,1])
C0877050 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,3])
C0521982 (UMLS CUI [3,1])
C0877050 (UMLS CUI [3,2])
C1710038 (UMLS CUI [3,3])
Cancer hormonal therapy Systemic | Disease Progression
Item
has received and whose disease progressed after one or two prior systemic hormonal anti-tumor therapies
boolean
C0877050 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
Zubrod Performance Status
Item
performance status of greater than or equal to 2 on the zubrod scale
boolean
C3714786 (UMLS CUI [1])
Life Expectancy
Item
predicted life expectancy of greater than or equal to 12 weeks
boolean
C0023671 (UMLS CUI [1])
Informed consent
Item
must give written informed consent
boolean
C0021430 (UMLS CUI [1])
Measurable Disease
Item
measurable disease according to the response evaluation criteria in solid tumors (recist) criteria
boolean
C1513041 (UMLS CUI [1])
Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
absolute granulocyte count of greater than 1,500/meql, platelet count greater than 75,000/meql, and a hemoglobin of greater than 10 g/dl
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
Liver function | Renal function | Serum total bilirubin measurement | Creatinine measurement, serum
Item
adequate liver and renal function as defined by a bilirubin of less than 1.5 times the upper limit of normal and a creatinine of less than 1.5 times the upper limit of normal
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Secondary malignant neoplasm of liver
Item
transaminases must be less than 2.5 times the upper limit of normal except for patients with liver metastases who may have transaminases less than 5 times the upper limit of normal.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
cancer treatment Due to Toxicities | Patient recovered
Item
the patient has recovered from all previous anti-cancer treatment related to toxicities to at least grade 1.
boolean
C0920425 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0600688 (UMLS CUI [1,3])
C1115804 (UMLS CUI [2])
Investigational New Drugs Previous Stop | TS 108 Start
Item
all previous investigational drugs must be stopped at least four weeks before commencement of treatment with tas-108.
boolean
C0013230 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0850893 (UMLS CUI [1,3])
C1435232 (UMLS CUI [2,1])
C0439659 (UMLS CUI [2,2])